Beam Therapeutics Inc. has made significant progress on its liver-targeted genetic disease franchise, with BEAM-302 potentially receiving accelerated approval from the FDA. The company also plans to submit a Biologics Licensing Application for risto-cel by the end of 2026. Additionally, Beam ended 2025 with $1.25 billion in cash, setting the stage for expected operating runway extension into 2029. The company aims to advance its precision genetic medicines with confidence and speed, delivering lasting benefits to patients with serious diseases.

In its liver-targeted genetic disease franchise, Beam’s lead program, BEAM-302, aims to treat alpha-1 antitrypsin deficiency (AATD). The company has reached an agreement with the FDA on a potential accelerated approval pathway based on AAT biomarkers. BEAM-301, targeting glycogen storage disease type Ia (GSDIa), is also progressing in clinical trials. Beam expects to announce a new program in the first half of 2026, expanding its pipeline for liver-targeted genetic diseases. The company is dedicated to revolutionizing genetic medicine with its precision base editing platform.

Beam’s hematology franchise focuses on treating sickle cell disease (SCD) with risto-cel, an investigational autologous cell therapy. The company aims to submit a Biologics Licensing Application for risto-cel by the end of 2026. Beam is also developing next-generation programs for SCD and hematology, using its advanced technologies to provide transformative therapies for patients. With a strong financial position, Beam is well-equipped to advance its pipeline and deliver innovative genetic medicines to those in need.

Read more at GlobeNewswire: Beam Therapeutics Sets Strategic Priorities for its Genetic